Cogentin (Benztropine Mesylate Injection)
برای این دارو، اطلاعات عمومی (فارسی) یافت نشد . برای افزودن اطلاعات فارسی به این دارو کلیک نمایید.
Cogentin (Benztropine Mesylate Injection)

COGENTIN®
(benztropine mesylate) Injection

DRUG DESCRIPTION

Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine.

It is designated chemically as 8-azabicyclo[3.2.1] octane, 3-(diphenylmethoxy)-,endo, methanesulfonate. Its empirical formula is C21H25NO•CH4O3S, and its structural formula is:

Benztropine mesylate structural formula illustration

Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54. COGENTIN* (Benztropine Mesylate) is supplied as a sterile injection for intravenous and intramuscular use.

Each milliliter of the injection contains:

Benztropine mesylate ..........1 mg
Sodium chloride ...............9 mg
Water for injection q.s. . ....1 mL

What are the possible side effects of benztropine (Cogentin)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • pounding heartbeats or fluttering in your chest;
  • feeling very weak;
  • feeling too weak to move;
  • confusion, hallucinations, unusual thoughts or behavior;
  • urinating less than usual or not at all;
  • severe constipation;
  • dry mouth that interferes with speech, swallowing, appetite, or...

Read All Potential Side Effects and See Pictures of Cogentin »

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

For use as an adjunct in the therapy of all forms of parkinsonism.

Useful also in the control of extrapyramidal disorders (except tardive dyskinesia — see PRECAUTIONS) due to neuroleptic drugs (e.g., phenothiazines).

DOSAGE AND ADMINISTRATION

Since there is no significant difference in onset of effect after intravenous or intramuscular injection, usually there is no need to use the intravenous route. The drug is quickly effective after either route, with improvement sometimes noticeable a few minutes after injection. In emergency situations, when the condition of the patient is alarming, 1 to 2 mL of the injection normally will provide quick relief. If the parkinsonian effect begins to return, the dose can be repeated.

Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five or six-day intervals to the smallest amount nec-essary for optimal relief. Increases should be made in increments of 0.5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions.

Postencephalitic and Idiopathic Parkinsonism —

The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.

As with any agent used in parkinsonism, dosage must be individualized according to age and weight, and the type of parkinsonism being treated. Generally, older patients, and thin patients cannot tolerate large doses. Most patients with postencephalitic parkinsonism need fairly large doses and tolerate them well. Patients with a poor mental outlook are usually poor candidates for therapy.

In idiopathic parkinsonism, therapy may be initiated with a single daily dose of 0.5 to 1 mg at bedtime. In some patients, this will be adequate; in others 4 to 6 mg a day may be required.

In postencephalitic parkinsonism, therapy may be initiated in most patients with 2 mg a day in one or more doses. In highly sensitive patients, therapy may be ini-tiated with 0.5 mg at bedtime, and increased as necessary.

Some patients experience greatest relief when given the entire dose at bedtime; others react more favorably to divided doses, two to four times a day. Frequently, one dose a day is sufficient, and divided doses may be unnecessary or undesirable.

The long duration of action of this drug makes it particularly suitable for bedtime medication when its effects may last throughout the night, enabling patients to turn in bed during the night more easily, and to rise in the morning.

When COGENTIN (benztropine mesylate injection) is started, do not terminate therapy with other antiparkinsonian agents abruptly. If the other agents are to be reduced or discontinued, it must be done gradually. Many patients obtain greatest relief with combination therapy.

COGENTIN (benztropine mesylate injection) may be used concomitantly with SINEMET* (Carbidopa-Levodopa), or with levodopa, in which case periodic dosage adjustment may be required in order to maintain optimum response.

Drug-Induced Extrapyramidal Disorders —

In treating extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), the recommended dosage is 1 to 4 mg once or twice a day parenterally. Dosage must be individualized according to the need of the patient. Some patients require more than recommended; others do not need as much.

In acute dystonic reactions, 1 to 2 mL of the injection usually relieves the condition quickly.

When extrapyramidal disorders develop soon after initiation of treatment with neuroleptic drugs (e.g., phenothiazines), they are likely to be transient. One to 2 mg of COGENTIN (benztropine mesylate injection) two or three times a day usually provides relief within one or two days. After one or two weeks, the drug should be withdrawn to determine the continued need for it. If such disorders recur, COGENTIN (benztropine mesylate injection) can be reinstituted.

Certain drug-induced extrapyramidal disorders that develop slowly may not respond to COGENTIN (benztropine mesylate injection) .

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

HOW SUPPLIED

Injection COGENTIN (benztropine mesylate injection) , 1 mg per mL, is a clear, colorless solution and is supplied in boxes of 5 x 2 mL ampuls.

NDC 67386-611-52

Manufactured by Merck & Co. Inc., Whitehouse Station, NJ 08889, U.S.A. for:OVATION Pharmaceuticals Deerfield, il 60015, u.s.a.
Revised SEPTEMBER 2005
* Registered trademark of Merck & Co., Inc., Whitehouse Station, NJ, U.S.A.
FDA rev date: 5/22/2001

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

SIDE EFFECTS

The adverse reactions below, most of which are anticholinergic in nature, have been reported and within each category are listed in order of decreasing severity.

Cardiovascular

Tachycardia.

Digestive

Paralytic ileus, constipation, vomiting, nausea, dry mouth.

If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily.

Slight reduction in dosage may control nausea and still give sufficient relief of symptoms. Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage.

Nervous System

Toxic psychosis, including confusion, disorientation, memory impairment, visual hallucinations; exacerbation of pre-existing psychotic symptoms; nervousness; depression; listlessness; numbness of fingers.

Special Senses

Blurred vision, dilated pupils.

Urogenital

Urinary retention, dysuria.

Metabolic/Immune or Skin

Occasionally, an allergic reaction, e.g., skin rash, develops. If this cannot be controlled by dosage reduction, the medication should be discontinued.

Other

Heat stroke, hyperthermia, fever.

Read the Cogentin (benztropine mesylate injection) Side Effects Center for a complete guide to possible side effects »

DRUG INTERACTIONS

Antipsychotic drugs such as phenothiazines or haloperidol; tricyclic antidepressants (see WARNINGS).

Pediatric use

Because of the atropine-like side effects, COGENTIN (benztropine mesylate injection) should be used with caution in pediatric patients over three years of age (see CONTRAINDICATIONS).

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

WARNINGS

Safe use in pregnancy has not been established.

COGENTIN (benztropine mesylate injection) may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.

When COGENTIN (benztropine mesylate injection) is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including COGENTIN (benztropine mesylate injection) , in combination with phenothiazines and/or tricyclic antidepressants.

Since COGENTIN (benztropine mesylate injection) contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidro-sis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.

PRECAUTIONS

General

Since COGENTIN (benztropine mesylate injection) has cumulative action, continued supervision is advisable. Patients with a tendency to tachycardia and patients with prostatic hypertrophy should be observed closely during treatment.

Dysuria may occur, but rarely becomes a problem. Urinary retention has been reported with COGENTIN (benztropine mesylate injection) .

The drug may cause complaints of weakness and inability to move particular muscle groups, especially in large doses. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event, dosage adjustment is required.

Mental confusion and excitement may occur with large doses, or in susceptible patients. Visual hallucinations have been reported occasionally. Furthermore, in the treatment of extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), in patients with mental disorders, occasionally there may be intensi-fication of mental symptoms. In such cases, antiparkinsonian drugs can precipitate a toxic psychosis. Patients with mental disorders should be kept under care-ful observation, especially at the beginning of treatment or if dosage is increased.

Tardive dyskinesia may appear in some patients on long-term therapy with phenothiazines and related agents, or may occur after therapy with these drugs has been discontinued. Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate them. COGENTIN (benztropine mesylate injection) is not recommended for use in patients with tardive dyskinesia.

The physician should be aware of the possible occurrence of glaucoma. Although the drug does not appear to have any adverse effect on simple glaucoma, it probably should not be used in angle-closure glaucoma.

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

OVERDOSE

Manifestations —

May be any of those seen in atropine poisoning or antihistamine overdosage: CNS depression, preceded or followed by stimulation; confu-sion; nervousness; listlessness; intensification of mental symptoms or toxic psychosis in patients with mental illness being treated with neuroleptic drugs (e.g., phenothiazines); hallucinations (especially visual); dizziness; muscle weakness; ataxia; dry mouth; mydriasis; blurred vision; palpitations; tachycardia; elevat-ed blood pressure; nausea; vomiting; dysuria; numbness of fingers; dysphagia; allergic reactions, e.g., skin rash; headache; hot, dry, flushed skin; delirium; coma; shock; convulsions; respiratory arrest; anhidrosis; hyperthermia; glaucoma; constipation.

Treatment —

Physostigmine salicylate, 1 to 2 mg, SC or IV, reportedly will reverse symptoms of anticholinergic intoxication.** A second injection may be given after 2 hours if required. Otherwise treatment is symptomatic and supportive. Induce emesis or perform gastric lavage (contraindicated in precomatose, convul-sive, or psychotic states). Maintain respiration. A short-acting barbiturate may be used for CNS excitement, but with caution to avoid subsequent depression; supportive care for depression (avoid convulsant stimulants such as picrotoxin, pentylenetetrazol, or bemegride); artificial respiration for severe respiratory depression; a local miotic for mydriasis and cycloplegia; ice bags or other cold applications and alcohol sponges for hyperpyrexia, a vasopressor and fluids for circulatory collapse. Darken room for photophobia.

CONTRAINDICATIONS

Hypersensitivity to any component of COGENTIN (benztropine mesylate injection) injection.

Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

** Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. 206: 1963-1965, Nov. 25, 1968.

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

CLINICAL PHARMACOLOGY

Action

COGENTIN (benztropine mesylate injection) possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism.

In the isolated guinea pig ileum, the anticholinergic activity of this drug is about equal to that of atropine; however, when administered orally to unanesthetized cats, it is only about half as active as atropine.

In laboratory animals, its antihistaminic activity and duration of action approach those of pyrilamine maleate.

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

PATIENT INFORMATION

No information provided. Please refer to the WARNINGS and PRECAUTIONS sectrions.

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

>

PATIENT INFORMATION

No information provided. Please refer to the WARNINGS and PRECAUTIONS sectrions.

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

COGENTIN®
(benztropine mesylate) Injection

DRUG DESCRIPTION

Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine.

It is designated chemically as 8-azabicyclo[3.2.1] octane, 3-(diphenylmethoxy)-,endo, methanesulfonate. Its empirical formula is C21H25NO•CH4O3S, and its structural formula is:

Benztropine mesylate structural formula illustration

Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54. COGENTIN* (Benztropine Mesylate) is supplied as a sterile injection for intravenous and intramuscular use.

Each milliliter of the injection contains:

Benztropine mesylate ..........1 mg
Sodium chloride ...............9 mg
Water for injection q.s. . ....1 mL

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

COGENTIN®
(benztropine mesylate) Injection

DRUG DESCRIPTION

Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine.

It is designated chemically as 8-azabicyclo[3.2.1] octane, 3-(diphenylmethoxy)-,endo, methanesulfonate. Its empirical formula is C21H25NO•CH4O3S, and its structural formula is:

Benztropine mesylate structural formula illustration

Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54. COGENTIN* (Benztropine Mesylate) is supplied as a sterile injection for intravenous and intramuscular use.

Each milliliter of the injection contains:

Benztropine mesylate ..........1 mg
Sodium chloride ...............9 mg
Water for injection q.s. . ....1 mL

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

COGENTIN®
(benztropine mesylate) Injection

DRUG DESCRIPTION

Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine.

It is designated chemically as 8-azabicyclo[3.2.1] octane, 3-(diphenylmethoxy)-,endo, methanesulfonate. Its empirical formula is C21H25NO•CH4O3S, and its structural formula is:

Benztropine mesylate structural formula illustration

Benztropine mesylate is a crystalline white powder, very soluble in water, and has a molecular weight of 403.54. COGENTIN* (Benztropine Mesylate) is supplied as a sterile injection for intravenous and intramuscular use.

Each milliliter of the injection contains:

Benztropine mesylate ..........1 mg
Sodium chloride ...............9 mg
Water for injection q.s. . ....1 mL

Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.

Cogentin Patient Information Including Side Effects

Brand Names: Cogentin

Generic Name: benztropine (Pronunciation: BENZ troe peen)

What is benztropine (Cogentin)?

Benztropine reduces the effects of certain chemicals in the body that may become unbalanced as a result of disease (such as Parkinson's), drug therapy, or other causes.

Benztropine is used to treat the symptoms of Parkinson's disease, such as muscle spasms, stiffness, tremors, sweating, drooling, and poor muscle control.

Benztropine is also used to treat and prevent these symptoms when they are caused by drugs such as chlorpromazine (Thorazine), fluphenazine (Prolixin), perphenazine (Trilafon), and others.

Benztropine may also be used for purposes not listed in this medication guide.

Benztropine 0.5 mg-IVA

round, white, imprinted with par 164

Benztropine 0.5 mg-UPS

round, white, imprinted with 832 BM 05

Benztropine 1 mg-IVA

oval, white, imprinted with par 165

Benztropine 1 mg-ROS

elliptical, white, imprinted with 832 BM1

Benztropine 2 mg-PAR

round, white, imprinted with par 166

Benztropine 2 mg-UPS

round, white, imprinted with 832 BM2

What are the possible side effects of benztropine (Cogentin)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • pounding heartbeats or fluttering in your chest;
  • feeling very weak;
  • feeling too weak to move;
  • confusion, hallucinations, unusual thoughts or behavior;
  • urinating less than usual or not at all;
  • severe constipation;
  • dry mouth that interferes with speech, swallowing, appetite, or eating;
  • feeling very thirsty or hot, being unable to urinate, heavy sweating, or hot and dry skin;
  • blurred vision, eye pain, or seeing halos around lights; or
  • twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs.

Less serious side effects may include:

  • depressed mood, memory problems;
  • drowsiness, feeling nervous or excited;
  • nausea, upset stomach;
  • dry mouth (mild);
  • double vision, increased sensitivity to light; or
  • numbness in your fingers;

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Cogentin (benztropine mesylate injection) Side Effects Center for a complete guide to possible side effects »

What is the most important information I should know about benztropine (Cogentin)?

You should not take this medication if you are allergic to benztropine, or if you are also taking a medication called pramlintide (Symlin).

Before you take benztropine, tell if you have glaucoma, kidney or liver disease, heart disease, high blood pressure, a history of heart attack or stroke, a breathing disorder, a nerve or muscle disorder, seizures, urination problems, overactive thyroid, mental illness, or a stomach or intestinal disorder.

Avoid taking a diarrhea medication or antacid within 2 hours before or after you take benztropine. Also avoid taking ketoconazole (Nizoral) within 2 hours after you take benztropine.

Benztropine may cause blurred vision or impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert and able to see clearly.

Avoid becoming overheated or dehydrated during exercise and in hot weather. Benztropine can decrease perspiration and you may be more prone to heat stroke.

Do not stop taking this medication without first talking to your doctor. Stopping suddenly may make your condition worse. You may need to use less and less before you stop the medication completely.

Side Effects Centers

Cogentin Patient Information including How Should I Take

What should I discuss with my healthcare provider before taking benztropine (Cogentin)?

You should not take this medication if you are allergic to benztropine, or if you are also taking a medication called pramlintide (Symlin).

To make sure you can safely take benztropine, tell your doctor if you have any of these other conditions:

  • glaucoma;
  • heart disease, a heart rhythm disorder, history of heart attack;
  • high or low blood pressure;
  • asthma, emphysema, or other breathing disorder;
  • kidney or liver disease;
  • a nerve disorder;
  • a muscle disorder such as myasthenia gravis;
  • seizures;
  • enlarged prostate, urination problems;
  • overactive thyroid;
  • mental illness or dementia;
  • stomach ulcer, reflux disease, hiatal hernia; or
  • ulcerative colitis, history of bowel obstruction, or other intestinal disorder.

It is not known whether benztropine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication.

Benztropine should not be given to a child younger than 3 years old.

It is not known whether benztropine passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take benztropine (Cogentin)?

Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Drink plenty of liquids while you are taking benztropine.

Benztropine is sometimes given up to 4 times daily, at meals and at bedtime. If you take benztropine only once per day, it may be best to take the medication at bedtime. Follow your doctor's instructions.

Benztropine can be taken with food to lessen stomach upset.

Your mouth may feel dry while taking benztropine. To prevent or relieve dry mouth, suck on a piece of sugar-free hard candy, chew sugar-free gum, drink water, chew on ice chips, or use a saliva substitute.

Dry mouth may lead to gum disease or cavities. Brush and floss your teeth regularly and see a dentist for routine check-ups while you are taking benztropine.

It may take up to 3 days before your symptoms improve. Keep using the medication as directed and tell your doctor if your symptoms do not improve or if they get worse.

Do not stop taking this medication without first talking to your doctor. Stopping suddenly may make your condition worse. You may need to use less and less before you stop the medication completely.

Store at room temperature away from moisture, heat, and light.

Side Effects Centers

Cogentin Patient Information including If I Miss a Dose

What happens if I miss a dose (Cogentin)?

Since benztropine is sometimes taken only when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose (Cogentin)?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose can cause confusion, severe dizziness, hallucinations, loss of balance or coordination, vomiting, heavy sweating, hot and dry skin, numbness, urinating less than usual, dilated pupils, fast or pounding heartbeats, muscle weakness, weak or shallow breathing, buzzing in your ears, seizures, and fainting.

What should I avoid while taking benztropine (Cogentin)?

Avoid taking a diarrhea medication (such as Kaopectate, Donnagel, or Rheaban) or an antacid (such as Amphojel, Maalox, Mylanta, Rolaids, Rulox, or Tums) within 2 hours before or after you take benztropine. These medications can make it harder for your body to absorb benztropine, which can make it less effective.

Also avoid taking ketoconazole (Nizoral) within 2 hours after you take benztropine. Benztropine can make it harder for your body to absorb ketoconazole.

Benztropine may cause blurred vision or impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert and able to see clearly.

Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.

Drinking alcohol can increase certain side effects of benztropine.

Avoid becoming overheated or dehydrated during exercise and in hot weather. Benztropine can decrease perspiration and you may be more prone to heat stroke.

What other drugs will affect benztropine (Cogentin)?

Before using benztropine, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by benztropine.

Tell your doctor about all other medications you use, especially:

  • amantadine (Symmetrel);
  • glycopyrrolate (Robinul);
  • mepenzolate (Cantil);
  • a diuretic (water pill);
  • potassium supplements (K-Lyte, K-Dur, Klor-Con, and others);
  • an antidepressant such as amitriptyline (Elavil, Vanatrip, Limbitrol), doxepin (Sinequan), nortriptyline (Pamelor), and others;
  • atropine (Atreza, Sal-Tropine), belladonna (Donnatal, and others), dimenhydrinate (Dramamine), meclizine (Antivert), methscopolamine (Pamine), or scopolamine (Transderm-Scop);
  • bladder or urinary medications such as darifenacin (Enablex), flavoxate (Urispas), oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), or solifenacin (Vesicare);
  • bronchodilators such as ipratropium (Atrovent) or tiotropium (Spiriva);
  • irritable bowel medications such as dicyclomine (Bentyl), hyoscyamine (Anaspaz, Cystospaz, Levsin, and others), or propantheline (Pro-Banthine);
  • medicine to treat Alzheimer's dementia, such as donepezil (Aricept) or galantamine (Razadyne); or
  • medicines to treat psychiatric disorders, such as chlorpromazine (Thorazine), fluphenazine (Permitil, Prolixin), haloperidol (Haldol); perphenazine (Trilafon), prochlorperazine (Compazine, Compro), promethazine (Pentazine, Phenergan, Anergan, Antinaus), thioridazine (Mellaril), or trifluoperazine (Stelazine).

This list is not complete and other drugs may interact with benztropine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about benztropine.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 7.01. Revision date: 3/31/2011.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com